GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Pieris Pharmaceuticals
Pieris Pharmaceuticals is a biotech company developing a new class of protein-based drugs. Its stock price is a story of rise thanks to partnerships with major pharmaceutical companies and subsequent decline due to clinical trial failures.
Share prices of companies in the market segment - Pharma other
Pieris Pharmaceuticals is a biotech company developing a new class of drugs based on anticalins for the treatment of respiratory diseases and cancer. We classified it in "Other Pharma." The chart below shows how investors value companies with unique technology platforms.
Broad Market Index - GURU.Markets
Pieris Pharmaceuticals is a biotech company developing a new class of drugs based on anticalins for the treatment of respiratory diseases and cancer. We classified it in "Other Pharma." The chart below shows how investors value companies with unique technology platforms.
Change in the price of a company, segment, and market as a whole per day
PIRS - Daily change in the company's share price Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its protein drugs.
Daily change in the price of a set of shares in a market segment - Pharma other
Pieris Pharmaceuticals was developing a new class of protein drugs (Anti-Clinics) but encountered failures in clinical trials. Its story exemplifies the risks of biotechnology. The chart below shows the volatility in this sector, illustrating how quickly a company's prospects can change.
Daily change in the price of a broad market stock, index - GURU.Markets
Pieris Pharmaceuticals is a pharmaceutical company developing new drugs. Its shares, like many in the sector, are volatile and react to news about clinical trials. These scientifically driven movements are part of the overall stock market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Pieris Pharmaceuticals
For Pieris Pharmaceuticals, year-over-year performance is a reflection of its Anticalin® platform. Its 12-month market capitalization is entirely dependent on clinical trial data. Partnerships with giants like AstraZeneca are key confirmation of the potential of its unique technology for creating a new class of protein drugs.
Annual dynamics of market capitalization of the market segment - Pharma other
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing a new class of protein-based therapeutics. Its stock performance is entirely dependent on the results of clinical trials and partnerships. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Pieris Pharmaceuticals, a biotech company plagued by research setbacks, tells the story of its struggle for survival. Its performance, compared to the market, reflects investors' confidence in the remaining drugs in its portfolio. It's a risky bet on the company's ability to recover.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Pieris Pharmaceuticals
Pieris is a biopharmaceutical company with a unique Anticalin platform. Its monthly performance is entirely dependent on progress in its clinical programs and its partnerships, particularly with AstraZeneca. Trial news is the primary driver.
Monthly dynamics of market capitalization of the market segment - Pharma other
Pieris Pharmaceuticals is developing a new class of protein-based drugs, called antagonists, for the treatment of respiratory diseases and oncology. The graph below illustrates the overall dynamics in the pharmaceutical sector, where innovative therapeutic platforms with unique properties are constantly being sought.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks often live in a world of their own, where clinical trial news trumps overall market trends. The chart below shows the pulse of the broader market. Does Pieris Pharmaceuticals move in sync with the broader market, or do its R&D developments create a completely separate story?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Pieris Pharmaceuticals
The weekly performance of Pieris, a biotech company developing a new class of protein-based therapeutics, reflects the risks and potential of its platform. Share prices are driven by clinical trial data and partnerships with major pharmaceutical companies.
Weekly dynamics of market capitalization of the market segment - Pharma other
Pieris Pharmaceuticals is developing a new class of protein drugs, Anticalin. This chart compares its volatile, news-driven performance with the pharmaceutical sector and helps us understand how much investors believe in its innovative scientific platform compared to other biotech approaches.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Pieris Pharmaceuticals is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether Pieris is operating in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are actually influencing its stock price.
Market capitalization of the company, segment and market as a whole
PIRS - Market capitalization of the company Pieris Pharmaceuticals
The Pieris market capitalization chart tells the story of a biotech company with a unique protein platform that suffered a major setback in clinical trials. Its collapse highlights the risks of drug development, where a single piece of news can wipe out nearly the entire company's value.
PIRS - Share of the company's market capitalization Pieris Pharmaceuticals within the market segment - Pharma other
Pieris Pharmaceuticals is developing a new class of protein-based drugs. Its share of the biotech sector's market capitalization reflects investors' bets on the potential of its unique Anticalin technology. The chart shows how its weighting changes based on progress in clinical trials and partnerships.
Market capitalization of the market segment - Pharma other
Pieris Pharmaceuticals is a biotech company developing a new class of protein-based drugs (Anticalins). The chart below shows the overall market capitalization of this sector. Its volatility reflects the long and risky journey the company is undertaking to prove the effectiveness of its unique scientific platform.
Market capitalization of all companies included in a broad market index - GURU.Markets
Pieris Pharmaceuticals is developing a new class of protein drugs. The market capitalization of such biotech companies is a bet on their unique scientific platform. Their volatility on the overall chart reflects how the market evaluates the risks and potential of completely new approaches to drug development.
Book value capitalization of the company, segment and market as a whole
PIRS - Book value capitalization of the company Pieris Pharmaceuticals
Pieris Pharmaceuticals' balance sheet consists of its capital and patents for the unique Anticalin platform for creating a new class of protein drugs. This is the real, scientific foundation for developing drugs against respiratory diseases and cancer. How has this innovative, yet risky, biotech asset evolved? The chart below shows its dynamics.
PIRS - Share of the company's book capitalization Pieris Pharmaceuticals within the market segment - Pharma other
Pieris Pharmaceuticals is developing a new class of protein drugs (Anticalins), which requires advanced R&D laboratories. The chart shows the share of these science-intensive tangible assets, reflecting the physical foundation of its innovation platform.
Market segment balance sheet capitalization - Pharma other
Pieris, a biopharmaceutical company developing a new class of proteins, has a capital-intensive R&D business. This requires the ownership of cutting-edge laboratories. The BCap_Seg chart for the biotech sector shows that breakthrough research requires a robust scientific infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Pieris Pharma's balance sheet is its Anticalin® scientific platform for creating a new class of therapeutic proteins. The company's assets are its intellectual capital and partnerships with major pharmaceutical companies. The chart shows how this science-intensive R&D asset compares to giants with manufacturing capabilities.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Pieris Pharmaceuticals
Pieris Pharmaceuticals is developing a new class of protein drugs. Its balance sheet represents the value of its Anticalin research platform. Its market capitalization represents investors' bet that this technology will lead to the creation of effective drugs. The chart reflects confidence in the company's scientific potential and future partnerships with pharma giants.
Market to book capitalization ratio in a market segment - Pharma other
Pieris Pharmaceuticals is a biotech company developing a new class of protein drugs called antacalins. Its market valuation on the chart is speculative and depends entirely on the success of its clinical programs and partnerships with major pharmaceutical companies.
Market to book capitalization ratio for the market as a whole
Pieris Pharmaceuticals is a biotech company whose value depends almost entirely on the success of its drug discovery platform. Its physical assets are minimal. This chart helps assess how high the premium for innovation and potential breakthroughs in biotech is compared to the market average.
Debts of the company, segment and market as a whole
PIRS - Company debts Pieris Pharmaceuticals
Pieris Pharmaceuticals, a biotech company developing a new class of anticalin proteins, is using capital to fund its clinical and preclinical programs. This chart shows how the company is raising funds to validate its innovative scientific platform, which could be applied to the treatment of respiratory diseases and oncology.
Market segment debts - Pharma other
Pieris Pharmaceuticals is a clinical-stage biotech company developing a new class of protein therapeutics. Like its peers, it relies entirely on equity and partner fees to fund its research. This chart illustrates the industry's typical financial model, with minimal to no debt.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Pieris Pharmaceuticals
Pieris Pharmaceuticals is a biotech company developing a new class of protein drugs. Its technology is in clinical trials. This chart shows the company's reliance on debt to finance its expensive and risky R&D, which is a direct measure of its financial vulnerability.
Market segment debt to market segment book capitalization - Pharma other
Pieris Pharmaceuticals is developing a new class of protein-based drugs (Anticalins) for the treatment of respiratory diseases and cancer. This is an innovative but unproven platform. The chart shows how aggressively the biotech sector uses debt, providing context for assessing Pieris's risks and potential.
Debt to book value of all companies in the market
Pieris Pharmaceuticals is developing a new class of proteins to treat various diseases, requiring significant and long-term investment in research. This chart, showing the overall market debt load, helps assess how the company's financial strategy compares to that of the innovative, high-risk biotech sector.
P/E of the company, segment and market as a whole
P/E - Pieris Pharmaceuticals
Pieris Pharmaceuticals is developing a new class of protein drugs called Anticalins for the treatment of respiratory diseases and oncology. This chart shows how investors value its unique scientific platform. The valuation depends on success in clinical trials and partnerships with major pharmaceutical companies.
P/E of the market segment - Pharma other
Biotechnology, where Pieris develops anticalin-based drugs, is an innovative field. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Pieris is valued as a scientific platform, and the industry benchmark serves as a benchmark for the company's potential value if its unique technology is successful.
P/E of the market as a whole
Pieris Pharmaceuticals is a biopharmaceutical company developing a new class of protein-based therapeutics. Its valuation is a pure bet on its scientific platform. It has no connection to the general economic cycles depicted by this chart. Pieris's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Pieris Pharmaceuticals
For Pieris Pharmaceuticals, a biopharmaceutical company with a platform for creating anticalin proteins, this chart illustrates market expectations for its clinical developments. It reflects investor confidence in the potential of this technology for treating respiratory diseases and cancer.
%20P%2FE%20Pieris%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Pieris-Pharmaceuticals&v=1772653266403 "Chart of the company's future (projected) P/E Pieris Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma other
Pieris Pharmaceuticals is developing a new class of protein therapeutics called Anticalins for the treatment of respiratory diseases and cancer. The company has partnerships with major pharmaceutical companies. The chart shows industry forecasts. This helps compare how the market views Pieris's innovative platform and the risks associated with its clinical development.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772653266407 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Pieris Pharmaceuticals is a biopharmaceutical company developing a new class of protein therapeutics. This is fundamental science, and the company's valuation reflects its belief in its platform. This chart shows the market's willingness to invest in science-intensive platform companies whose commercial potential may only be realized in the distant future.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772653266417 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Pieris Pharmaceuticals
Pieris Pharmaceuticals is a biopharmaceutical company developing a new class of proteins (Anticalins) for the treatment of respiratory diseases and cancer. Being in the clinical stage, its financial results represent R&D losses. This chart shows the cost of innovation and the long journey from scientific concept to potential cure.
Profit of companies in the market segment - Pharma other
Pieris Pharmaceuticals is developing a new class of proteins called antacalins for the treatment of respiratory diseases and cancer. This chart, which reflects the pharmaceutical sector's profitability, highlights the investment climate. Their innovative platform is attracting partners from major pharmaceutical companies, but ultimate success depends on the results of clinical trials of their unique compounds.
Overall market profit
Pieris Pharmaceuticals is developing a new class of protein drugs called antacalins for the treatment of respiratory diseases and cancer. Like any research-stage biotech company, its prospects depend on the success of clinical trials. This overall market return chart reflects the investment climate, which determines Pieris's ability to fund its development.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Pieris Pharmaceuticals
Pieris Pharmaceuticals is developing a new class of anticalin proteins for the treatment of respiratory diseases and oncology. Their technology allows for the creation of inhaled medications. This graph reflects analysts' expectations for the success of clinical trials and partnerships with major pharmaceutical companies, which is a bet on this innovative platform.
%20profit%20of%20the%20company%20Pieris%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Pieris-Pharmaceuticals&v=1772653266510 "Graph of future (projected) profit of the company Pieris Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma other
Pieris Pharmaceuticals is a biotech company developing a new class of proteins called Anticalins for the treatment of respiratory diseases and cancer. Its future depends on the success of its innovative platform. This biotech chart reflects investor interest in breakthrough technologies and their willingness to fund companies developing new classes of drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772653266552 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
Pieris Pharmaceuticals is developing a new class of protein-based drugs. The company's success depends on its scientific platform and clinical trial results. The overall profit forecast, shown in this chart, influences the willingness of investors and large pharmaceutical companies to invest in innovative but risky technologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772653266568 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Pieris Pharmaceuticals
Pieris Pharmaceuticals is a biopharmaceutical company developing a new class of proteins, antacalins, for the treatment of respiratory diseases and cancer. For a clinical-stage company, this chart is key. It shows how investors view its unique scientific platform and the potential for future revenue from partnerships and its own products.
P/S market segment - Pharma other
Pieris Pharmaceuticals is developing a new class of protein drugs called anticalins for the treatment of respiratory diseases and cancer. The company's valuation is based on the potential of its unique scientific platform. This chart, which reflects the average valuation in the biotech industry, helps investors understand how expectations for Pieris' innovative technology align with industry trends.
P/S of the market as a whole
Pieris Pharmaceuticals is a biopharmaceutical company developing a new class of proteins called anticalins for the treatment of respiratory diseases, anemia, and cancer. This chart, which reflects revenue estimates for real businesses, highlights that Pieris's valuation is a bet on its unique scientific platform and the potential to create revolutionary drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Pieris Pharmaceuticals
Pieris Pharmaceuticals is a biotech company developing a new class of proteins called anthcalins for the treatment of respiratory diseases and cancer. Its platform has the potential to create unique drugs. This chart reflects investors' confidence in the potential of its technology to develop a pipeline of drugs in partnership with major pharmaceutical companies.
%20P%2FS%20Pieris%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Pieris-Pharmaceuticals&v=1772653266652 "The graph of the company's future (projected) P/S Pieris Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma other
Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of proteins called Anticalins for the treatment of respiratory diseases and cancer. This chart reflects average revenue expectations in the biotech sector and provides an indication of how highly the market values Pieris's innovative platform.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772653266663 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
Pieris Pharmaceuticals is developing a new class of protein drugs called anticalins for the treatment of respiratory diseases and oncology. This chart shows investor expectations for revenue growth. The company's innovative platform could lead to more effective and safer drugs, fueling investor optimism about the future of the biotech sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772653266710 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Pieris Pharmaceuticals
This chart illustrates the revenue of Pieris Pharmaceuticals, a clinical-stage biopharmaceutical company developing a new class of protein-based therapeutics. Its revenue is generated not from sales, but from upfront and milestone payments from major pharmaceutical partners. The dynamics reflect progress in clinical development.
Sales of companies in the market segment - Pharma other
Pieris Pharmaceuticals is a biotech company developing a new class of drugs based on the Anticalin protein for the treatment of respiratory diseases and cancer. This graph illustrates the growth of the pharmaceutical market. Pieris's unique platform enables the creation of drugs with multiple advantages, and its partnerships with major pharmaceutical companies highlight the potential of this technology.
Overall market sales
Pieris Pharmaceuticals is a biotech company developing a new class of protein-based therapeutics. Its market capitalization is based on the potential of its scientific platform. The overall economic climate, reflected in this chart, influences investor willingness to finance long-term, capital-intensive projects in the biotech sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Pieris Pharmaceuticals
Pieris Pharmaceuticals is a biotech company developing a new class of protein drugs called "anticalins." Future revenue depends on the success of clinical trials and partnerships with major pharmaceutical companies. The chart reflects analysts' confidence in the potential of this innovative platform.
%20sales%20of%20the%20company%20Pieris%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Pieris-Pharmaceuticals&v=1772653266762 "Schedule of future (projected) sales of the company Pieris Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma other
Pieris Pharmaceuticals is developing a new class of protein drugs, called antacalins, for the treatment of respiratory diseases and cancer. Their unique structure allows them to address therapeutic challenges inaccessible to traditional antibodies. This graph shows the outlook for the entire pharmaceutical market, where innovative platforms like Pieris's have the potential to create new treatment standards.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772653266784 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Pieris Pharmaceuticals is a clinical-stage biotech company developing a new class of proteins called antacalins for the treatment of respiratory diseases and cancer. This chart, reflecting sentiment in the biotech sector, impacts the company's ability to attract funding to advance its innovative platform through clinical trials.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772653266790 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Pieris Pharmaceuticals
Pieris Pharmaceuticals is developing a new class of protein drugs (Antacalins) for the treatment of respiratory diseases and cancer. While in the clinical stage, the company incurs significant R&D expenses. This chart shows its net losses—investments in a unique scientific platform that could spawn a whole family of innovative drugs.
Market segment marginality - Pharma other
Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of proteins called Anticalins for the treatment of respiratory diseases and cancer. Profitability is a long-term goal. This chart reflects clinical trial costs. Investors evaluate it in the context of the potential of their unique protein platform.
Market marginality as a whole
Pieris Pharmaceuticals is a biotech company developing a new class of proteins called Anticalins for the treatment of respiratory diseases and cancer. This is an innovative platform. This overall profitability chart is irrelevant for them. Their value and future depend solely on the results of clinical trials and the potential of their unique technology.
Employees in the company, segment and market as a whole
Number of employees in the company Pieris Pharmaceuticals
Pieris Pharmaceuticals is a clinical-stage biotech company. It works with a small team of scientists to develop a new class of protein-based therapeutics. This chart reflects its compact, R&D-focused structure, typical of a biotech company advancing its own scientific platform.
Share of the company's employees Pieris Pharmaceuticals within the market segment - Pharma other
Pieris Pharmaceuticals is developing a new class of protein drugs called antacalins for the treatment of respiratory diseases and cancer. This chart shows the share of scientific talent the company is attracting in this innovative field of biotechnology. The growth in this indicator reflects the progress of its unique research platform and the expansion of its clinical programs.
Number of employees in the market segment - Pharma other
Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a novel class of anticalin proteins. This chart shows employment trends in the innovative biopharmaceuticals sector. The growing number of scientists reflects progress in clinical trials and investor confidence in the potential of this unique technology platform for treating various diseases.
Number of employees in the market as a whole
Pieris Pharmaceuticals is a biotech company developing a new class of protein-based therapeutics. Its development requires significant and ongoing investment in R&D. Overall economic stability, illustrated by this graph, influences the availability of venture capital and the willingness of large pharmaceutical companies to partner, which is critical for the company.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Pieris Pharmaceuticals (PIRS)
Pieris Pharmaceuticals is a biotech company developing a new class of proteins (Anticalins) for the treatment of respiratory diseases and cancer. This is pure R&D. The chart shows that the company's entire market value is derived from its unique scientific platform. The market capitalization per employee here reflects not labor productivity, but rather the investors' belief that their technology will lead to breakthrough drugs.
%20of%20the%20company%20Pieris%20Pharmaceuticals%20(PIRS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Pieris-Pharmaceuticals-PIRS&v=1772653266850 "Chart of market capitalization per employee (in thousands of dollars) of the company Pieris Pharmaceuticals (PIRS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Pieris Pharmaceuticals is a biotech company developing a new class of proteins called antacalins for the treatment of respiratory diseases and cancer. Its valuation is based on its unique scientific platform. This chart demonstrates the high valuation of its cutting-edge technologies and intellectual property per scientist.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772653266887 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Pieris Pharmaceuticals is developing a new class of protein drugs (Anticalins) for the treatment of cancer and respiratory diseases. The chart illustrates the valuation of the scientific platform. It shows how the market values their unique technology, where the contribution of a small team of scientists can lead to the creation of a new class of drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772653266896 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Pieris Pharmaceuticals (PIRS)
Pieris Pharmaceuticals is a clinical-stage biotech developing a new class of proteins (Anticalins) for the treatment of respiratory diseases and cancer. This is R&D. This chart shows capital burn: the amount the company spends on each scientist using their proprietary drug discovery platform.
%20Chart%20Pieris%20Pharmaceuticals%20(PIRS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Pieris-Pharmaceuticals-PIRS&v=1772653266903 "Company Profit Per Employee (in thousands of dollars) Chart Pieris Pharmaceuticals (PIRS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Pieris Pharmaceuticals is a clinical-stage biotechnology company developing Antikalin, a new class of protein-based drugs. This metric (loss per employee) reflects the high cost of R&D and clinical trials to create this new drug platform.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772653266919 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Pieris Pharmaceuticals (PIRS) is a clinical-stage biotech developing a new class of proteins (Anticalins). This is an R&D business. The company is unprofitable. (Ticker symbol PVLA, same business.) This chart shows the company's capital burn rate: operating loss per research team.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772653266949 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Pieris Pharmaceuticals (PIRS)
Pieris Pharmaceuticals is a biotech company developing a new class of protein therapeutics called Anticalins. This chart reflects the progress of monetizing its unique scientific platform. Revenue growth at this stage is likely due to upfront payments from major pharmaceutical industry partners.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Pieris-Pharmaceuticals-PIRS&v=1772653266951 "Sales chart per company employee Pieris Pharmaceuticals (PIRS)")
Sales per employee in the market segment - Pharma other
Pieris Pharmaceuticals (PIRS) is a biotech company developing a new class of proteins (Anticalins) for the treatment of respiratory diseases and cancer. While in the clinical stage, their revenue (if any) comes from partnerships. This chart shows how productive their R&D team is in monetizing their developments per scientist.
Sales per employee for the market as a whole
Pieris Pharmaceuticals (PIRS) is a clinical-stage biotech company developing a new class of proteins (Anticalins) for the treatment of respiratory diseases and oncology. The company has no commercial revenue yet. This chart illustrates a typical R&D situation: the research staff generates data and patents, but not revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Pieris Pharmaceuticals (PIRS)
Pieris Pharmaceuticals is a biotech company developing a new class of proteins called "Anti-Clinics." The bearish sentiment shown in this chart reflects investor bets that this new and unproven scientific platform will fail to produce effective or safe drugs and will fail in the clinic.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Pieris-Pharmaceuticals-PIRS&v=1772653266974 "Short Shares Chart for the Company Pieris Pharmaceuticals (PIRS)")
Shares shorted by market segment - Pharma other
Pieris Pharmaceuticals (PIRS) is a biopharmaceutical company developing a new class of proteins (Anticalin) for the treatment of respiratory diseases and immuno-oncology. This chart reflects the overall investor pessimism toward the entire biotech sector. It shows the overall market distrust in new, unproven therapeutic platforms and concerns about funding.
Shares shorted by the overall market
Pieris is a biotech company focused on oncology. It's a classic R&D story. This chart measures the overall level of fear in the market. When it's high, investors are unwilling to fund multi-year clinical trials. They see "another unprofitable company" and sell, fearing the "cash" will run out before success.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Pieris Pharmaceuticals (PIRS)
Pieris Pharmaceuticals is a biotech company developing a new class of proteins (Anticalins) for the treatment of respiratory diseases and cancer. The company's shares are binary and dependent on trial data. This oscillator tracks investor sentiment, indicating peak optimism (above 70) or deep despair (below 30) following news.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Pieris-Pharmaceuticals-PIRS&v=1772653267163 "RSI 14 indicator chart for the company's stock Pieris Pharmaceuticals (PIRS)")
RSI 14 Market Segment - Pharma other
Pieris Pharmaceuticals is a biotech company developing the Anticalin platform, a class of proteins intended to be an alternative to antibodies. The company has experienced R&D setbacks. This chart reflects the overall sentiment in the biotech sector. It helps assess whether this speculative industry is oversold or overheated.
RSI 14 for the overall market
Pieris Pharma (PIRS) is a biotech R&D company. Like everyone in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PIRS (Pieris Pharmaceuticals)
Pieris (PIRS) is a biotech developing a new class of proteins (Anticalins) for the treatment of respiratory diseases and oncology. This chart shows the average target price. It reflects analysts' speculative assessment of this unique scientific platform and its chances of success in clinical trials after recent setbacks.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PIRS-Pieris-Pharmaceuticals&v=1772653267300 "A chart showing analyst consensus forecasts for the expected stock price. PIRS (Pieris Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price PIRS (Pieris Pharmaceuticals)
Pieris (PIRS) is a biotech company developing "anticalins," a new class of proteins that promise to be superior to antibodies in the treatment of cancer and asthma. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their view of this R&D platform after past setbacks.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PIRS-Pieris-Pharmaceuticals&v=1772653267309 "A chart showing the difference between the consensus forecast and the actual stock price. PIRS (Pieris Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Pieris is an R&D biotech company developing "Anti-Clins"—small proteins that are intended to be a "smart" alternative to bulky antibodies (for example, in inhalers). This chart displays analysts' overall expectations for the *entire* pharma sector. It shows whether experts believe in this new R&D platform.
Analysts' consensus forecast for the overall market share price
Pieris Pharmaceuticals (PIRS) is a biopharmaceutical company with a unique R&D platform. They are developing Anticalins, a new class of protein drugs for the treatment of cancer and respiratory diseases. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough but high-risk R&D platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Pieris Pharmaceuticals
Pieris is a biotech platform. Their signature product is Anticalins, a new class of small proteins (smaller than antibodies) that they claim can be inhaled (for asthma) or attack cancer. This graph is a summary of their R&D failure. It reflects their (disastrous) clinical data and their (desperate) struggle to save their R&D platform.
AKIMA Market Segment Index - Pharma other
Pieris Pharmaceuticals (PIRS) is another pharma company with new technology. They are developing Anticalins—proteins they hope will be superior to antibodies in the treatment of cancer and asthma. This chart compares their composite index to the sector, showing how their Anticalin platform outperforms the competition.
The AKIM Index for the overall market
Pieris Pharmaceuticals is a biotech company developing drugs based on Anticalins (Anticalin) for the treatment of respiratory diseases and cancer. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this technology platform, which is undergoing restructuring, compares to overall economic trends.
